
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Advertising (2) Apply Advertising filter
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Remove Biologicals filter Biologicals (2)
- Complementary medicines (7) Apply Complementary medicines filter
- Remove Cosmetics filter Cosmetics (0)
- Remove Disinfectants/Sterilants filter Disinfectants/Sterilants (0)
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Remove Listed medicines filter Listed medicines (2)
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Medical devices safety (1) Apply Medical devices safety filter
- Remove Medicines filter Medicines (2)
- Medicines safety (1) Apply Medicines safety filter
- Remove OTC medicines filter OTC medicines (12)
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Prescription medicines (5) Apply Prescription medicines filter
- Scheduling (55) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Therapeutic goods regulation (2) Apply Therapeutic goods regulation filter
- (-) Remove OTC medicines filter OTC medicines
- (-) Remove Disinfectants/Sterilants filter Disinfectants/Sterilants
- (-) Remove Cosmetics filter Cosmetics
- (-) Remove Medicines filter Medicines
- (-) Remove Listed medicines filter Listed medicines
- (-) Remove Biologicals filter Biologicals
Repurposing of medicines
Closed on 1 April 2022
Priority Review pathway for biologicals: feasibility, potential eligibility criteria and determination process
Closed on 28 March 2022
Consultation on Extemporaneous Compounding of Emergency Medicines
Closed on 7 February 2022
Consultation on potential regulatory options for 'export only' biologicals
Closed on 20 December 2021
Proposed minor changes to Required Advisory Statements for Medicine Labels (RASML): Chlorhexidine, hydrocortisone, ibuprofen
Closed on 17 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Melatonin
Closed on 17 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Triptans
Closed on 17 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Mometasone
Closed on 17 September 2021
Proposed changes to the Permissible Ingredients Determination: Low-negligible risk changes 2021-22
Closed on 15 September 2021